146 related articles for article (PubMed ID: 37904690)
1. Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study.
Sykes DL; Van der Feltz-Cornelis CM; Holdsworth L; Hart SP; O'Halloran J; Holding S; Crooks MG
Immun Inflamm Dis; 2023 Oct; 11(10):e1052. PubMed ID: 37904690
[TBL] [Abstract][Full Text] [Related]
2. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study.
Maamar M; Artime A; Pariente E; Fierro P; Ruiz Y; Gutiérrez S; Tobalina M; Díaz-Salazar S; Ramos C; Olmos JM; Hernández JL
Curr Med Res Opin; 2022 Jun; 38(6):901-909. PubMed ID: 35166141
[TBL] [Abstract][Full Text] [Related]
3. 'Immune-inflammatory markers & clinical characteristics for outcomes in hospitalized SARS-CoV-2 infected patients of Pakistan: a retrospective analysis'.
Khalid A; Aqeel RF; Nawaz A; Ahmad J; Fatima ST; Shahid S; Rao AA; Aktas G; Ijaz S; Shehryar M
Hematology; 2023 Dec; 28(1):2199629. PubMed ID: 37408482
[TBL] [Abstract][Full Text] [Related]
4. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.
Infante M; Buoso A; Pieri M; Lupisella S; Nuccetelli M; Bernardini S; Fabbri A; Iannetta M; Andreoni M; Colizzi V; Morello M
J Am Nutr Assoc; 2022; 41(3):250-265. PubMed ID: 33600292
[TBL] [Abstract][Full Text] [Related]
5. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study.
Fernández-de-Las-Peñas C; Rodríguez-Jiménez J; Fuensalida-Novo S; Palacios-Ceña M; Gómez-Mayordomo V; Florencio LL; Hernández-Barrera V; Arendt-Nielsen L
Pain; 2021 Dec; 162(12):2832-2840. PubMed ID: 33863864
[TBL] [Abstract][Full Text] [Related]
6. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.
Premraj L; Kannapadi NV; Briggs J; Seal SM; Battaglini D; Fanning J; Suen J; Robba C; Fraser J; Cho SM
J Neurol Sci; 2022 Mar; 434():120162. PubMed ID: 35121209
[TBL] [Abstract][Full Text] [Related]
7. Serological biomarkers of COVID-19 severity at hospital admission are not related to long-term post-COVID pain symptoms in hospitalized COVID-19 survivors.
Fernández-de-Las-Peñas C; Ryan-Murua P; de-la-Llave-Rincón AI; Gómez-Mayordomo V; Arendt-Nielsen L; Torres-Macho J
Pain; 2022 Nov; 163(11):2112-2117. PubMed ID: 35121694
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients.
Velavan TP; Kuk S; Linh LTK; Lamsfus Calle C; Lalremruata A; Pallerla SR; Kreidenweiss A; Held J; Esen M; Gabor J; Neurohr EM; Shamsrizi P; Fathi A; Biecker E; Berg CP; Ramharter M; Addo MM; Kreuels B; Kremsner PG
Sci Rep; 2021 Jul; 11(1):14471. PubMed ID: 34262116
[TBL] [Abstract][Full Text] [Related]
9. Serological Biomarkers at Hospital Admission Are Not Related to Long-Term Post-COVID Fatigue and Dyspnea in COVID-19 Survivors.
Fernández-de-Las-Peñas C; Ryan-Murua P; Rodríguez-Jiménez J; Palacios-Ceña M; Arendt-Nielsen L; Torres-Macho J
Respiration; 2022; 101(7):658-665. PubMed ID: 35381597
[TBL] [Abstract][Full Text] [Related]
10. Acute Muscle Mass Loss Predicts Long-Term Fatigue, Myalgia, and Health Care Costs in COVID-19 Survivors.
Gil S; de Oliveira Júnior GN; Sarti FM; Filho WJ; Longobardi I; Turri JAO; Shinjo SK; Ferriolli E; Avelino-Silva TJ; Busse AL; Gualano B; Roschel H
J Am Med Dir Assoc; 2023 Jan; 24(1):10-16. PubMed ID: 36493804
[TBL] [Abstract][Full Text] [Related]
11. Assessment of diagnostic and prognostic laboratory biomarkers in severe COVID-19 patients admitted to intensive care unit.
Fawzy M; Ahmed SS; Abdelhady SA
Egypt J Immunol; 2023 Jan; 30(1):1-13. PubMed ID: 36588448
[TBL] [Abstract][Full Text] [Related]
12. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis.
Ziakas A; Gavrilidis S; Giannoglou G; Souliou E; Gemitzis K; Kalampalika D; Vayona MA; Pidonia I; Parharidis G; Louridas G
Angiology; 2006; 57(3):283-93. PubMed ID: 16703188
[TBL] [Abstract][Full Text] [Related]
13. Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Yitao Z; Mu C; Ling Z; Shiyao C; Jiaojie X; Zhichong C; Huajing P; Maode O; Kanglin C; Mao OY; Xiaoneng M; Weijie Z
Curr Med Res Opin; 2021 Mar; 37(3):385-391. PubMed ID: 33459077
[TBL] [Abstract][Full Text] [Related]
14. Mortality in Patients of COVID-19 Infection: Biochemical Markers and its Cut-off Values for Predicting Outcome.
Yousaf MN; Sarwar S; Tarique S; Ahmed M; Tahir H
J Coll Physicians Surg Pak; 2022 Jan; 32(1):37-41. PubMed ID: 34983145
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal changes in inflammatory biomarkers among patients with COVID-19: A nationwide study in Iceland.
Oskarsdottir T; Sigurdsson MI; Palsson R; Eythorsson E
Acta Anaesthesiol Scand; 2022 Sep; 66(8):969-977. PubMed ID: 35748857
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics of children with SARS-CoV-2 Omicron variant infection in Kunming].
Yang JW; Tang CH; Dai M; Duan J; Li YH; Yang J; Yang T; Gao Y; Ban D; Zhu JC; Yuan TY; Li Y; Fu HM
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):922-927. PubMed ID: 37803860
[No Abstract] [Full Text] [Related]
17. Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.
Farid E; Sridharan K; Alsegai OA; Khawaja SA; Mansoor EJ; Teraifi NA; Qahtani MA; Salman JA
Biomark Med; 2021 Jun; 15(8):541-549. PubMed ID: 33988463
[No Abstract] [Full Text] [Related]
18. Clinical laboratory characteristics in patients with suspected COVID-19: One single-institution experience.
Fei F; Smith JA; Cao L
J Med Virol; 2021 Mar; 93(3):1665-1671. PubMed ID: 32946118
[TBL] [Abstract][Full Text] [Related]
19. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
20. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort.
Ghosn J; Piroth L; Epaulard O; Le Turnier P; Mentré F; Bachelet D; Laouénan C;
Clin Microbiol Infect; 2021 Jul; 27(7):1041.e1-1041.e4. PubMed ID: 34125067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
